Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, presents the results of some preclinical and clinical trials investigating the effects of venetoclax in combination with proteasome inhibitors at the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden. Dr Kumar discusses the drugs venetoclax has been combined with and the results of these combinations, all of which seem promising regardless of whether the patients had previously been exposed to drugs of the same kind. For more Venetoclax coverage see this video entitled “Is Venetoclax + Ibrutinib better Ibrutinib Monotherapy in CLL?”
Promising outlooks for venetoclax combinations for MM
